Skip to content

NovoCure NVCR Debt Issuance Proceeds

Debt Issuance Proceeds at other companies

Medtronic logo
MedtronicMDT
$1.75B
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$30M
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$174.1M+12.3%
Gross profit$135.1M+16.0%
Operating income-$67.4M-78.1%
Net income-$71.1M-107%
EPS (diluted)-$0.62-100%

Balance sheet

See full
Cash & equivalents$87.5M-31.2%
Total debt$39.5M-2.1%
Total equity$330.7M-8.6%
Total assets$787.9M-36.9%

Cash flow

See full
Operating cash flow-$13.5M+62.1%
CapEx$5.2M-51.4%
Free cash flow-$18.7M+59.7%

Valuation

See full
Market cap$1.7B-36.7%
Enterprise value$1.66B-36.3%
P/S2.5×-1.8×

Profitability

See full
Gross margin75.2%-2.0pp
Operating margin-27.2%+0.4pp
Net margin-25.7%-0.7pp
FCF margin-7.1%-2.0pp

Returns & leverage

See full
Return on equity-50%+5.4pp
Debt / equity0.1×0.0×
Current ratio2.9×+1.4×

Where this comes from

Reported directly by NovoCure in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfLongTermDebt.

The official record: NovoCure’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about NovoCure's debt issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is NovoCure's debt issuance proceeds?
NovoCure (NVCR) reported debt issuance proceeds of $0 in Q1 2026.
What does debt issuance proceeds mean?
Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.